 | • レポートコード：GIR-107A14847 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、乏突起膠腫治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。乏突起膠腫治療の種類別市場規模（アリセルチブ、ベバシズマブ、CDX-1401、ダサチニブ、DCVax-L、IMA-950、その他）、用途別市場規模（クリニック、病院、ASC）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・乏突起膠腫治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AngioChem Inc、Boehringer Ingelheim GmbH、Bristol-Myers Squibb Co、Cavion LLC、Celldex Therapeutics Inc、Eli Lilly and Co、F. Hoffmann-La Roche Ltd、Immatics Biotechnologies GmbH、Ipsen SA、Leadiant Biosciences Inc、Millennium Pharmaceuticals Inc、Northwest Biotherapeutics Inc、Novartis AG、Pfizer Inc、Tocagen Inc ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：アリセルチブ、ベバシズマブ、CDX-1401、ダサチニブ、DCVax-L、IMA-950、その他 ・用途別分析2016年-2026年：クリニック、病院、ASC ・乏突起膠腫治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・乏突起膠腫治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・乏突起膠腫治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・乏突起膠腫治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・乏突起膠腫治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Oligodendroglioma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Oligodendroglioma Treatment size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Oligodendroglioma Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Oligodendroglioma Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Alisertib
Bevacizumab
CDX-1401
Dasatinib
DCVax-L
IMA-950
Others
Market segment by Application can be divided into
Clinic
Hospital
ASCs
The key market players for global Oligodendroglioma Treatment market are listed below:
AngioChem Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cavion LLC
Celldex Therapeutics Inc
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Immatics Biotechnologies GmbH
Ipsen SA
Leadiant Biosciences Inc
Millennium Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Pfizer Inc
Tocagen Inc
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Oligodendroglioma Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Oligodendroglioma Treatment, with price, sales, revenue and global market share of Oligodendroglioma Treatment from 2019 to 2021.
Chapter 3, the Oligodendroglioma Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oligodendroglioma Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Oligodendroglioma Treatment market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Oligodendroglioma Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Oligodendroglioma Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Oligodendroglioma Treatment Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Alisertib
1.2.3 Bevacizumab
1.2.4 CDX-1401
1.2.5 Dasatinib
1.2.6 DCVax-L
1.2.7 IMA-950
1.2.8 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Oligodendroglioma Treatment Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Clinic
1.3.3 Hospital
1.3.4 ASCs
1.4 Global Oligodendroglioma Treatment Market Size & Forecast
1.4.1 Global Oligodendroglioma Treatment Sales in Value (2016-2026))
1.4.2 Global Oligodendroglioma Treatment Sales in Volume (2016-2026)
1.4.3 Global Oligodendroglioma Treatment Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Oligodendroglioma Treatment Production Capacity Analysis
1.5.1 Global Oligodendroglioma Treatment Total Production Capacity (2016-2026)
1.5.2 Global Oligodendroglioma Treatment Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Oligodendroglioma Treatment Market Drivers
1.6.2 Oligodendroglioma Treatment Market Restraints
1.6.3 Oligodendroglioma Treatment Trends Analysis
2 Manufacturers Profiles
2.1 AngioChem Inc
2.1.1 AngioChem Inc Details
2.1.2 AngioChem Inc Major Business
2.1.3 AngioChem Inc Oligodendroglioma Treatment Product and Services
2.1.4 AngioChem Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Boehringer Ingelheim GmbH
2.2.1 Boehringer Ingelheim GmbH Details
2.2.2 Boehringer Ingelheim GmbH Major Business
2.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product and Services
2.2.4 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Bristol-Myers Squibb Co
2.3.1 Bristol-Myers Squibb Co Details
2.3.2 Bristol-Myers Squibb Co Major Business
2.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Product and Services
2.3.4 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Cavion LLC
2.4.1 Cavion LLC Details
2.4.2 Cavion LLC Major Business
2.4.3 Cavion LLC Oligodendroglioma Treatment Product and Services
2.4.4 Cavion LLC Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Celldex Therapeutics Inc
2.5.1 Celldex Therapeutics Inc Details
2.5.2 Celldex Therapeutics Inc Major Business
2.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Product and Services
2.5.4 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Eli Lilly and Co
2.6.1 Eli Lilly and Co Details
2.6.2 Eli Lilly and Co Major Business
2.6.3 Eli Lilly and Co Oligodendroglioma Treatment Product and Services
2.6.4 Eli Lilly and Co Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 F. Hoffmann-La Roche Ltd
2.7.1 F. Hoffmann-La Roche Ltd Details
2.7.2 F. Hoffmann-La Roche Ltd Major Business
2.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product and Services
2.7.4 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Immatics Biotechnologies GmbH
2.8.1 Immatics Biotechnologies GmbH Details
2.8.2 Immatics Biotechnologies GmbH Major Business
2.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product and Services
2.8.4 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Ipsen SA
2.9.1 Ipsen SA Details
2.9.2 Ipsen SA Major Business
2.9.3 Ipsen SA Oligodendroglioma Treatment Product and Services
2.9.4 Ipsen SA Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 Leadiant Biosciences Inc
2.10.1 Leadiant Biosciences Inc Details
2.10.2 Leadiant Biosciences Inc Major Business
2.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Product and Services
2.10.4 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Millennium Pharmaceuticals Inc
2.11.1 Millennium Pharmaceuticals Inc Details
2.11.2 Millennium Pharmaceuticals Inc Major Business
2.11.3 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product and Services
2.11.4 Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 Northwest Biotherapeutics Inc
2.12.1 Northwest Biotherapeutics Inc Details
2.12.2 Northwest Biotherapeutics Inc Major Business
2.12.3 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product and Services
2.12.4 Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.13 Novartis AG
2.13.1 Novartis AG Details
2.13.2 Novartis AG Major Business
2.13.3 Novartis AG Oligodendroglioma Treatment Product and Services
2.13.4 Novartis AG Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.14 Pfizer Inc
2.14.1 Pfizer Inc Details
2.14.2 Pfizer Inc Major Business
2.14.3 Pfizer Inc Oligodendroglioma Treatment Product and Services
2.14.4 Pfizer Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.15 Tocagen Inc
2.15.1 Tocagen Inc Details
2.15.2 Tocagen Inc Major Business
2.15.3 Tocagen Inc Oligodendroglioma Treatment Product and Services
2.15.4 Tocagen Inc Oligodendroglioma Treatment Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Oligodendroglioma Treatment Sales by Manufacturer
3.1 Global Oligodendroglioma Treatment Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Oligodendroglioma Treatment Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Oligodendroglioma Treatment
3.4 Market Concentration Rate
3.4.1 Top 3 Oligodendroglioma Treatment Manufacturer Market Share
3.4.2 Top 6 Oligodendroglioma Treatment Manufacturer Market Share
3.5 Global Oligodendroglioma Treatment Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Oligodendroglioma Treatment Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Oligodendroglioma Treatment Market Size by Region
4.1.1 Global Oligodendroglioma Treatment Sales in Volume by Region (2016-2026)
4.1.2 Global Oligodendroglioma Treatment Revenue by Region (2016-2026)
4.2 North America Oligodendroglioma Treatment Revenue (2016-2026)
4.3 Europe Oligodendroglioma Treatment Revenue (2016-2026)
4.4 Asia-Pacific Oligodendroglioma Treatment Revenue (2016-2026)
4.5 South America Oligodendroglioma Treatment Revenue (2016-2026)
4.6 Middle East and Africa Oligodendroglioma Treatment Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Oligodendroglioma Treatment Sales in Volume by Type (2016-2026)
5.2 Global Oligodendroglioma Treatment Revenue by Type (2016-2026)
5.3 Global Oligodendroglioma Treatment Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Oligodendroglioma Treatment Sales in Volume by Application (2016-2026)
6.2 Global Oligodendroglioma Treatment Revenue by Application (2016-2026)
6.3 Global Oligodendroglioma Treatment Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Oligodendroglioma Treatment Sales by Type (2016-2026)
7.2 North America Oligodendroglioma Treatment Sales by Application (2016-2026)
7.3 North America Oligodendroglioma Treatment Market Size by Country
7.3.1 North America Oligodendroglioma Treatment Sales in Volume by Country (2016-2026)
7.3.2 North America Oligodendroglioma Treatment Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Oligodendroglioma Treatment Sales by Type (2016-2026)
8.2 Europe Oligodendroglioma Treatment Sales by Application (2016-2026)
8.3 Europe Oligodendroglioma Treatment Market Size by Country
8.3.1 Europe Oligodendroglioma Treatment Sales in Volume by Country (2016-2026)
8.3.2 Europe Oligodendroglioma Treatment Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Oligodendroglioma Treatment Sales by Type (2016-2026)
9.2 Asia-Pacific Oligodendroglioma Treatment Sales by Application (2016-2026)
9.3 Asia-Pacific Oligodendroglioma Treatment Market Size by Region
9.3.1 Asia-Pacific Oligodendroglioma Treatment Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Oligodendroglioma Treatment Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Oligodendroglioma Treatment Sales by Type (2016-2026)
10.2 South America Oligodendroglioma Treatment Sales by Application (2016-2026)
10.3 South America Oligodendroglioma Treatment Market Size by Country
10.3.1 South America Oligodendroglioma Treatment Sales in Volume by Country (2016-2026)
10.3.2 South America Oligodendroglioma Treatment Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Oligodendroglioma Treatment Sales by Type (2016-2026)
11.2 Middle East & Africa Oligodendroglioma Treatment Sales by Application (2016-2026)
11.3 Middle East & Africa Oligodendroglioma Treatment Market Size by Country
11.3.1 Middle East & Africa Oligodendroglioma Treatment Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Oligodendroglioma Treatment Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Oligodendroglioma Treatment Typical Distributors
12.3 Oligodendroglioma Treatment Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Table 1. Global Oligodendroglioma Treatment Revenue by Type, (USD Million), 2021-2026
Table 2. Global Oligodendroglioma Treatment Revenue by Application, (USD Million), 2021-2026
Table 3. AngioChem Inc Basic Information, Manufacturing Base and Competitors
Table 4. AngioChem Inc Major Business
Table 5. AngioChem Inc Oligodendroglioma Treatment Product and Services
Table 6. AngioChem Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Boehringer Ingelheim GmbH Basic Information, Manufacturing Base and Competitors
Table 8. Boehringer Ingelheim GmbH Major Business
Table 9. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Product and Services
Table 10. Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Bristol-Myers Squibb Co Basic Information, Manufacturing Base and Competitors
Table 12. Bristol-Myers Squibb Co Major Business
Table 13. Bristol-Myers Squibb Co Oligodendroglioma Treatment Product and Services
Table 14. Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Cavion LLC Basic Information, Manufacturing Base and Competitors
Table 16. Cavion LLC Major Business
Table 17. Cavion LLC Oligodendroglioma Treatment Product and Services
Table 18. Cavion LLC Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Celldex Therapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 20. Celldex Therapeutics Inc Major Business
Table 21. Celldex Therapeutics Inc Oligodendroglioma Treatment Product and Services
Table 22. Celldex Therapeutics Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Eli Lilly and Co Basic Information, Manufacturing Base and Competitors
Table 24. Eli Lilly and Co Major Business
Table 25. Eli Lilly and Co Oligodendroglioma Treatment Product and Services
Table 26. Eli Lilly and Co Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. F. Hoffmann-La Roche Ltd Basic Information, Manufacturing Base and Competitors
Table 28. F. Hoffmann-La Roche Ltd Major Business
Table 29. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Product and Services
Table 30. F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 31. Immatics Biotechnologies GmbH Basic Information, Manufacturing Base and Competitors
Table 32. Immatics Biotechnologies GmbH Major Business
Table 33. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Product and Services
Table 34. Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 35. Ipsen SA Basic Information, Manufacturing Base and Competitors
Table 36. Ipsen SA Major Business
Table 37. Ipsen SA Oligodendroglioma Treatment Product and Services
Table 38. Ipsen SA Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 39. Leadiant Biosciences Inc Basic Information, Manufacturing Base and Competitors
Table 40. Leadiant Biosciences Inc Major Business
Table 41. Leadiant Biosciences Inc Oligodendroglioma Treatment Product and Services
Table 42. Leadiant Biosciences Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 43. Millennium Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 44. Millennium Pharmaceuticals Inc Major Business
Table 45. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Product and Services
Table 46. Millennium Pharmaceuticals Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 47. Northwest Biotherapeutics Inc Basic Information, Manufacturing Base and Competitors
Table 48. Northwest Biotherapeutics Inc Major Business
Table 49. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Product and Services
Table 50. Northwest Biotherapeutics Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 51. Novartis AG Basic Information, Manufacturing Base and Competitors
Table 52. Novartis AG Major Business
Table 53. Novartis AG Oligodendroglioma Treatment Product and Services
Table 54. Novartis AG Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 55. Pfizer Inc Basic Information, Manufacturing Base and Competitors
Table 56. Pfizer Inc Major Business
Table 57. Pfizer Inc Oligodendroglioma Treatment Product and Services
Table 58. Pfizer Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 59. Tocagen Inc Basic Information, Manufacturing Base and Competitors
Table 60. Tocagen Inc Major Business
Table 61. Tocagen Inc Oligodendroglioma Treatment Product and Services
Table 62. Tocagen Inc Oligodendroglioma Treatment Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 63. Global Oligodendroglioma Treatment Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 64. Global Oligodendroglioma Treatment Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 65. Market Position of Manufacturers in Oligodendroglioma Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 66. Global Oligodendroglioma Treatment Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 67. Head Office and Oligodendroglioma Treatment Production Site of Key Manufacturer
Table 68. Oligodendroglioma Treatment New Entrant and Capacity Expansion Plans
Table 69. Oligodendroglioma Treatment Mergers & Acquisitions in the Past Five Years
Table 70. Global Oligodendroglioma Treatment Sales by Region (2016-2021e) & (K Pcs)
Table 71. Global Oligodendroglioma Treatment Sales by Region (2021-2026) & (K Pcs)
Table 72. Global Oligodendroglioma Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 73. Global Oligodendroglioma Treatment Revenue by Region (2021-2026) & (USD Million)
Table 74. Global Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 75. Global Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 76. Global Oligodendroglioma Treatment Revenue by Type (2016-2021e) & (USD Million)
Table 77. Global Oligodendroglioma Treatment Revenue by Type (2021-2026) & (USD Million)
Table 78. Global Oligodendroglioma Treatment Price by Type (2016-2021e) & (USD/Pcs)
Table 79. Global Oligodendroglioma Treatment Price by Type (2021-2026) & (USD/Pcs)
Table 80. Global Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 81. Global Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 82. Global Oligodendroglioma Treatment Revenue by Application (2016-2021e) & (USD Million)
Table 83. Global Oligodendroglioma Treatment Revenue by Application (2021-2026) & (USD Million)
Table 84. Global Oligodendroglioma Treatment Price by Application (2016-2021e) & (USD/Pcs)
Table 85. Global Oligodendroglioma Treatment Price by Application (2021-2026) & (USD/Pcs)
Table 86. North America Oligodendroglioma Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 87. North America Oligodendroglioma Treatment Sales by Country (2021-2026) & (K Pcs)
Table 88. North America Oligodendroglioma Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 89. North America Oligodendroglioma Treatment Revenue by Country (2021-2026) & (USD Million)
Table 90. North America Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 91. North America Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 92. North America Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 93. North America Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 94. Europe Oligodendroglioma Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 95. Europe Oligodendroglioma Treatment Sales by Country (2021-2026) & (K Pcs)
Table 96. Europe Oligodendroglioma Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 97. Europe Oligodendroglioma Treatment Revenue by Country (2021-2026) & (USD Million)
Table 98. Europe Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 99. Europe Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 100. Europe Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 101. Europe Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 102. Asia-Pacific Oligodendroglioma Treatment Sales by Region (2016-2021e) & (K Pcs)
Table 103. Asia-Pacific Oligodendroglioma Treatment Sales by Region (2021-2026) & (K Pcs)
Table 104. Asia-Pacific Oligodendroglioma Treatment Revenue by Region (2016-2021e) & (USD Million)
Table 105. Asia-Pacific Oligodendroglioma Treatment Revenue by Region (2021-2026) & (USD Million)
Table 106. Asia-Pacific Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 107. Asia-Pacific Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 108. Asia-Pacific Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 109. Asia-Pacific Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 110. South America Oligodendroglioma Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 111. South America Oligodendroglioma Treatment Sales by Country (2021-2026) & (K Pcs)
Table 112. South America Oligodendroglioma Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 113. South America Oligodendroglioma Treatment Revenue by Country (2021-2026) & (USD Million)
Table 114. South America Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 115. South America Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 116. South America Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 117. South America Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 118. Middle East & Africa Oligodendroglioma Treatment Sales by Country (2016-2021e) & (K Pcs)
Table 119. Middle East & Africa Oligodendroglioma Treatment Sales by Country (2021-2026) & (K Pcs)
Table 120. Middle East & Africa Oligodendroglioma Treatment Revenue by Country (2016-2021e) & (USD Million)
Table 121. Middle East & Africa Oligodendroglioma Treatment Revenue by Country (2021-2026) & (USD Million)
Table 122. Middle East & Africa Oligodendroglioma Treatment Sales by Type (2016-2021e) & (K Pcs)
Table 123. Middle East & Africa Oligodendroglioma Treatment Sales by Type (2021-2026) & (K Pcs)
Table 124. Middle East & Africa Oligodendroglioma Treatment Sales by Application (2016-2021e) & (K Pcs)
Table 125. Middle East & Africa Oligodendroglioma Treatment Sales by Application (2021-2026) & (K Pcs)
Table 126. Direct Channel Pros & Cons
Table 127. Indirect Channel Pros & Cons
Table 128. Oligodendroglioma Treatment Typical Distributors
Table 129. Oligodendroglioma Treatment Typical Customers
List of Figures
Figure 1. Oligodendroglioma Treatment Picture
Figure 2. Global Oligodendroglioma Treatment Sales Market Share by Type in 2020
Figure 3. Alisertib
Figure 4. Bevacizumab
Figure 5. CDX-1401
Figure 6. Dasatinib
Figure 7. DCVax-L
Figure 8. IMA-950
Figure 9. Others
Figure 10. Global Oligodendroglioma Treatment Sales Market Share by Application in 2020
Figure 11. Clinic
Figure 12. Hospital
Figure 13. ASCs
Figure 14. Global Oligodendroglioma Treatment Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 15. Global Oligodendroglioma Treatment Market Size and Forecast (2016-2026) & (USD Million)
Figure 16. Global Oligodendroglioma Treatment Sales (2016-2026) & (K Pcs)
Figure 17. Global Oligodendroglioma Treatment Price by Type (2016-2026) & (USD/Pcs)
Figure 18. Global Oligodendroglioma Treatment Production Capacity (2016-2026) & (K Pcs)
Figure 19. Global Oligodendroglioma Treatment Production Capacity by Geographic Region: 2020 VS 2021
Figure 20. Oligodendroglioma Treatment Market Drivers
Figure 21. Oligodendroglioma Treatment Market Restraints
Figure 22. Oligodendroglioma Treatment Market Trends
Figure 23. Global Oligodendroglioma Treatment Sales Market Share by Manufacturer in 2020
Figure 24. Global Oligodendroglioma Treatment Revenue Market Share by Manufacturer in 2020
Figure 25. Oligodendroglioma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 26. Top 3 Oligodendroglioma Treatment Manufacturer (Revenue) Market Share in 2020
Figure 27. Top 6 Oligodendroglioma Treatment Manufacturer (Revenue) Market Share in 2020
Figure 28. Global Oligodendroglioma Treatment Sales Market Share by Region (2016-2026)
Figure 29. Global Oligodendroglioma Treatment Revenue Market Share by Region (2016-2026)
Figure 30. North America Oligodendroglioma Treatment Revenue (2016-2026) & (USD Million)
Figure 31. Europe Oligodendroglioma Treatment Revenue (2016-2026) & (USD Million)
Figure 32. Asia-Pacific Oligodendroglioma Treatment Revenue (2016-2026) & (USD Million)
Figure 33. South America Oligodendroglioma Treatment Revenue (2016-2026) & (USD Million)
Figure 34. Middle East & Africa Oligodendroglioma Treatment Revenue (2016-2026) & (USD Million)
Figure 35. Global Oligodendroglioma Treatment Sales Market Share by Type (2016-2026)
Figure 36. Global Oligodendroglioma Treatment Revenue Market Share by Type (2016-2026)
Figure 37. Global Oligodendroglioma Treatment Price by Type (2016-2026) & (USD/Pcs)
Figure 38. Global Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 39. Global Oligodendroglioma Treatment Revenue Market Share by Application (2016-2026)
Figure 40. Global Oligodendroglioma Treatment Price by Application (2016-2026) & (USD/Pcs)
Figure 41. North America Oligodendroglioma Treatment Sales Market Share by Type (2016-2026)
Figure 42. North America Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 43. North America Oligodendroglioma Treatment Sales Market Share by Country (2016-2026)
Figure 44. North America Oligodendroglioma Treatment Revenue Market Share by Country (2016-2026)
Figure 45. United States Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Canada Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Mexico Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Europe Oligodendroglioma Treatment Sales Market Share by Type (2016-2026)
Figure 49. Europe Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 50. Europe Oligodendroglioma Treatment Sales Market Share by Country (2016-2026)
Figure 51. Europe Oligodendroglioma Treatment Revenue Market Share by Country (2016-2026)
Figure 52. Germany Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Oligodendroglioma Treatment Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Oligodendroglioma Treatment Sales Market Share by Region (2016-2026)
Figure 60. Asia-Pacific Oligodendroglioma Treatment Revenue Market Share by Region (2016-2026)
Figure 61. China Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Korea Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Oligodendroglioma Treatment Sales Market Share by Type (2016-2026)
Figure 68. South America Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 69. South America Oligodendroglioma Treatment Sales Market Share by Country (2016-2026)
Figure 70. South America Oligodendroglioma Treatment Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Type (2016-2026)
Figure 74. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Application (2016-2026)
Figure 75. Middle East & Africa Oligodendroglioma Treatment Sales Market Share by Country (2016-2026)
Figure 76. Middle East & Africa Oligodendroglioma Treatment Revenue Market Share by Country (2016-2026)
Figure 77. Turkey Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Egypt Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. South Africa Oligodendroglioma Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source
乏突起膠腫治療市場：世界及び中国市場分析・予測（～2024年） Oligodendroglioma Treatment Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Oligodendroglioma Treatment industry with a focus on the Chinese market. The report provides key statistics on the market status of the Oligodendrogli…- 世界の統合失調感情障害治療市場 2021：企業別、地域別、種類・用途別 The Schizoaffective Disorders Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, t…
- 世界のレイノー病治療市場 2021：企業別、地域別、種類・用途別 The Raynauds Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界の末期腎疾患治療市場 2021：企業別、地域別、種類・用途別 The End-Stage Kidney Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, tr…
- 世界の胸腺がん治療市場 2021：企業別、地域別、種類・用途別 The Thymic Carcinoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…